Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

DALLAS, May 2, 2024  — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in six presentations at the ARVO Annual Meeting, taking place May 5-9, 2024 in Seattle. The management team will be present at the conference and available to meet at the Nanoscope Therapeutics booth #4620.

Details for the presentations are as follows:

Presentation Title: Longitudinal BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 12-month results from a Phase 2b/3 randomized, sham-controlled, patient- and assessor-masked clinical trial (RESTORE)
Presentation Number: 2137
Presentation Type: Paper Session
Session Title: Retinitis Pigmentosa
Session Date: May 6, 2024
Session Time: 4:15 – 4:30 p.m. PT
Location: 612 – Seattle Convention Center – Arch Building
Presenter: Allen C. Ho, MD, Chief Medical Advisor

Abstract Title: Test-retest Agreement of the Freiburg Visual Acuity Test in Ultra-low Vision
Abstract/Poster Number: A0223
Session Type: Poster Session
Session Title: Low Vision Performance Assessment
Session Date: May 7, 2024
Session Time: 1:15 – 3:00 p.m. PT
Location: Exhibit Hall – Seattle Convention Center
Presenter: Samuel Barone, MD, Chief Medical Officer

Abstract Title: Longitudinal BCVA Analysis of Patients with Stargardt Disease and Macular Degeneration Treated With MCO-010, a Mutation-Agnostic Optogenetic Therapy: 48-Week Results From a Phase 2a Clinical Trial (STARLIGHT)
Abstract/Poster Number: B0094
Session Type: Poster Session
Session Title: Pediatric Ophthalmology and Inherited Eye Diseases
Session Date: May 8, 2024
Session Time: 2:15 – 4:00 p.m. PT
Location: Exhibit Hall – Seattle Convention Center
Presenter: Vinit B. Mahajan, MD, PhD, Professor of Ophthalmology at Stanford University

Abstract Title: Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in mouse models of retinitis pigmentosa
Abstract/Poster Number: B0293
Session Type: Poster Session
Session Title: Gene and Cell Therapies and Other Novel Therapeutics I
Session Date: May 8, 2024
Session Time: 2:15 – 4:00 p.m. PT
Location: Exhibit Hall – Seattle Convention Center
Presenter: Subrata Batabyal, PhD, Director, Non-Clinical Development

Abstract Title: Characterization of a Broadband Ambient Light Activatable Multi-Characteristic Opsin Supporting its Superior Performance in Restoring Vision
Abstract/Poster Number: B0924
Session Type: Poster Session
Session Title: Gene and Cell Therapies and Other Novel Therapeutics II
Session Date: May 9, 2024
Session Time: 8:00 – 9:45 a.m. PT
Location: Exhibit Hall – Seattle Convention Center
Presenter: Samarendra Mohanty, PhD, President and Chief Scientific Officer

Abstract Title: In Vivo Efficacy of a Novel Multi-Characteristic Opsin (MCO-010) in a Mouse Model of Leber Congenital Amaurosis
Abstract/Poster Number: B0942
Session Type: Poster Session
Session Title: Gene and Cell Therapies and Other Novel Therapeutics II
Session Date: May 9, 2024
Session Time: 8:00 – 9:45 a.m. PT
Location: Exhibit Hall – Seattle Convention Center
Presenter: Najam Sharif, PhD, DSc, Vice President of Global Research and Development

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently announced the 100-week data from RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both RP and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to age-related macular degeneration.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

On May 2, 2024   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Dr. Mohanty obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.